Alx Oncology (NASDAQ: ALXO) — Company Overview, News & Financial Data
Alx Oncology is a clinical-stage biotechnology firm developing therapies targeting cancer with its expertise in CD47 blockade.
Alx Oncology
Alx Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology firm focused on developing therapies for patients battling cancer. It leverages its expertise in CD47 blockade to create treatments that aim to enhance the body's immune response against tumors. The company has multiple projects in the pipeline, including lead candidate ALX148, designed for a variety of hematologic and solid malignancies. Alx Oncology's goal is to develop innovative, effective cancer treatments that improve patient outcomes across the globe. Through strategic collaborations and cutting-edge research, it strives to unlock new possibilities in cancer therapy, advancing towards key clinical milestones.
Snapshot
Operations
Products and/or services of Alx Oncology
- ASPEN-03: This clinical trial investigates the combination of ALX148 (their investigational drug) with pembrolizumab (Keytruda) for the treatment of advanced head and neck squamous cell carcinoma (HNSCC) in patients with PD-L1 expressing tumors.
- ASPEN-04: This clinical trial explores the effectiveness of combining ALX148 with pembrolizumab (Keytruda) and standard chemotherapy for treating advanced HNSCC in patients who haven't received prior treatment.
- ASPEN-06: This trial focuses on evaluating the potential of ALX148 (also known as Evorpacept) as a single agent in treating advanced HER2-positive gastric cancer.
- ASPEN-07: This trial investigates the combination of ALX148 (Evorpacept) with enfortumab vedotin for the treatment of subjects with urothelial carcinoma.
Alx Oncology executive team
- Jason W. LettmannCEO & Director
- Harish ShantharamChief Financial Officer
- Shelly WongSenior VP of Finance & Chief Accounting Officer
- Barbara J. KlenckeChief Medical Officer
- Jeff E. KnightChief Development & Operating Officer
- Michael ListgartenGeneral Counsel
- Athanasios TsiatisSenior Vice President of Clinical Development
- Lin Yeong-LiangSenior Vice President of Drug Safety & Pharmacovigilance
- Lisa SauerSenior Vice President of Regulatory Affairs & Quality Assurance
- Sue NaimSenior Vice President of Clinical Operations
Latest news about Alx Oncology
Key financials
Reported results for Alx Oncology , in USD.
- Market cap
- 178.4M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -104M | -101.7M | |
| 0 | -142.5M | -134.9M | |
| 0 | -170.3M | -160.8M | |
| 0 | -127.4M | -123.5M |